share_log

Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target

Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target

康泰克医疗公司被卡洛菲茨杰拉德证券重申其超额增持的评级,继续维持其16美元的目标股价。
Benzinga ·  2024/09/20 22:56  · 评级/大行评级

Cantor Fitzgerald analyst Sarah James reiterates Health Catalyst (NASDAQ:HCAT) with a Overweight and maintains $16 price target.

康腾菲兹分析师Sarah James重申对health catalyst(纳斯达克:HCAT)持有超配评级,并维持16美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发